Cortex's CEO to Speak at the Roth Capital Partners Growth Stock Conference on February 19, 2004.Business Editors IRVINE, Calif.--(BUSINESS WIRE)--Feb. 10, 2004 Roger G. Stoll, Ph.D., Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cortex Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : COR), will speak at the 16th Annual Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, Growth Stock Conference on Thursday, February 19, 2004 at 9:30 AM (PST PST Paroxysmal supraventricular tachycardia, see there ). Cortex is one of 225 invited companies to present at this conference to be held at the St. Regis Monarch Beach Resort & Spa in Dana Point, CA on February 16-19, 2004. A live and archived webcast of the presentation will be accessible at http://www.vcall.com/CEPage.asp?ID=85811. About Cortex Pharmaceuticals: Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , Alzheimer's disease and anxiety disorders. (http://www.cortexpharm.com/) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion